Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO.PA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$66.92M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Valerio Therapeutics S.A.Valerio Therapeutics S.A.-9.5-8683%--55.1
$-0.16

Current Fair Value

137.6% downside

Overvalued by 137.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$66.92 Million
Enterprise Value$79.10 Million
Earnings per Share$-0.03
Beta2.14
Outstanding Shares154,364,273

Return

Return on Equity8683.26%ROE
Return on Assets-111.83%
Return on Invested Capital-106.29%

Valuation & Multiples

P/E Ratio-9.51P/E Ratio
PEG-0.92PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.43Price to Book Ratio
Enterprise Value to Revenue10.72
Enterprise Value to EBIT-6.9
Enterprise Value to Net Income-4
Total Debt to Enterprise0.16
Debt to Equity-55.12Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 2, 2026
EPS
-$0.02
Reported
Revenue
$3.10 M
Reported

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Valerio Therapeutics S.A.

25 employees
CEO: Gilles Besin

Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their f...